Image

Transnasal Induction of Normothermia for Neurogenic Fever

Transnasal Induction of Normothermia for Neurogenic Fever

Recruiting
18-85 years
All
Phase N/A

Powered by AI

Overview

The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.

Eligibility

Inclusion Criteria:

  1. Admitted to an Intensive Care Unit for a planned stay of at least 24 hours with a diagnosis of ischemic or hemorrhagic stroke, seizure, or metabolic encephalopathy.
  2. Ages 18-85 years, inclusive.
  3. Patient has fever ≥ 38.3°C and ≤ 38.9°C at the time of treatment initiation.
  4. Patient is orally intubated or has tracheostomy tube and is mechanically ventilated.
  5. Glasgow Coma Scale score of 3-11, inclusive.
  6. Must have informed consent from the patient or the legally authorized representative (LAR) making decisions for the patient.

Exclusion Criteria:

  1. Intubation is contraindicated.
  2. Weight of ≤ 100lb or ≥ 250lb.
  3. Active/ongoing epistaxis.
  4. Known or suspected pregnancy.
  5. Participation in another ongoing investigational study.
  6. Prisoners and/or patients for whom no LAR is available.
  7. Patient is in airborne/droplet disease isolation protocol.
  8. Patient is or suspected to be immunocompromised.
  9. Nasal septal deviations (per standard of care CT scan; any degree).
  10. Chronic rhinosinusitis.
  11. Traumatic brain injury.
  12. Prior skull-base surgery.
  13. Penetrating cranial trauma.
  14. Recent nasal trauma or anterior base skull fracture.
  15. Any condition for which transnasal air flow would be contraindicated.
  16. Refractory hypoxemia (partial pressure of oxygen in arterial blood (paO2) below 60 torr or oxyhemoglobin saturation below 90% despite endotracheal intubation, mechanical ventilation, and provision of supplemental oxygen of up to 0.60).
  17. Refractory hypercarbia (partial pressure of carbon dioxide in arterial blood (paCO2) above 50 torr despite endotracheal intubation and conventional mechanical ventilation).

Study details
    Stroke
    Ischemic
    Stroke Hemorrhagic
    Seizures
    Metabolic Encephalopathy

NCT06038513

CoolTech LLC

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.